Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Apellis Pharmaceuticals Inc (NQ: APLS ) 32.51 -4.22 (-11.49%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Apellis Pharmaceuticals Inc < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > What's Going With Apellis Pharmaceuticals Stock Friday? September 20, 2024 Apellis Pharmaceuticals shares are moving lower after the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its June 2024 negative opinion following... Via Benzinga Apellis Stock Hammered After Eye Drug Gets A Third European Rejection September 20, 2024 The company is "out of European approval options" for its embattled geographic atrophy drug, says one analyst. Via Investor's Business Daily Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination September 20, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Analyst Scoreboard: 15 Ratings For Apellis Pharmaceuticals September 13, 2024 Via Benzinga Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 06, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know August 02, 2024 Via Benzinga Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights July 17, 2024 Via Benzinga Apellis Pharmaceuticals to Present at Upcoming Investor Conferences August 29, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Wedbush Just Raised its Price Target on These 7 Stocks: August 12, 2024 August 13, 2024 New Wedbush price targets have been issued for each of the following seven stocks, including a few that may come as a surprise to some. Via InvestorPlace Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases August 08, 2024 Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan for C3 glomerulopathy and IC-MPGN. The study met primary and secondary... Via Benzinga Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN August 08, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire What Analysts Are Saying About Apellis Pharmaceuticals Stock June 28, 2024 Via Benzinga Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts May 28, 2024 Via Benzinga In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals May 08, 2024 Via Benzinga Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 06, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results August 01, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results July 18, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting July 09, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session June 28, 2024 Via Benzinga Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU June 28, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA) June 10, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference June 05, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress May 24, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street May 14, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire APLS Stock Earnings: Apellis Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 May 07, 2024 APLS stock results show that Apellis Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. Via InvestorPlace Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results May 07, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference May 06, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting May 01, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA) April 26, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results April 23, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.